This study based on the stratification of the PMS population has the potential to allow for better patient selection in clinical trials, identifying candidates that are metabolically predisposed to optimal responses to hGH and/or IGF-1 and minimal or no side effects. This evidence concerns the gene IGF1 and premenstrual tension.